← Eichor
Study identifier: NCT04423211 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Condition: Biochemically Recurrent Prostate Carcinoma · Metastatic Prostate Carcinoma · Prostate Adenocarcinoma  ·  Sponsor: ECOG-ACRIN Cancer Research Group

PhasePhase 3
Planned participants804
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatm…

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (342)

Anchorage Associates in Radiation MedicineAnchorage, Alaska, United StatesRecruiting
Alaska Breast Care and Surgery LLCAnchorage, Alaska, United StatesRecruiting
Alaska Oncology and Hematology LLCAnchorage, Alaska, United StatesRecruiting
Alaska Women's Cancer CareAnchorage, Alaska, United StatesRecruiting
Anchorage Oncology CentreAnchorage, Alaska, United StatesSuspended
Katmai Oncology GroupAnchorage, Alaska, United StatesRecruiting
Providence Alaska Medical CenterAnchorage, Alaska, United StatesRecruiting
Fairbanks Memorial HospitalFairbanks, Alaska, United StatesSuspended
Cancer Center at Saint Joseph'sPhoenix, Arizona, United StatesRecruiting
Mercy Hospital Fort SmithFort Smith, Arkansas, United StatesRecruiting
Mission Hope Medical Oncology - Arroyo GrandeArroyo Grande, California, United StatesRecruiting
Providence Saint Joseph Medical Center/Disney Family Cancer CenterBurbank, California, United StatesRecruiting

+ 330 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04423211